Large market footprint Enterix has sold over 40 million FIT tests globally since 2020, indicating strong market adoption and potential for scale in new regions or channels.

Non stool handling The InSure ONE and ColoVantage Home tests offer stool-free processing and no refrigeration, presenting a compelling value proposition for both patients and providers, and opening opportunities with point-of-care partners and remote screening programs.

Regulatory ready FDA-registered and TGA-licensed manufacturing facilities with an additional NATA-accredited lab position Enterix to expand regulatory-compliant distribution and potential partnerships in the US and Australia.

Affordable screening Low-cost annual screening tests create a favorable entry point for payer discussions, employer health programs, and community screening initiatives, enabling upsell opportunities with clinics and health systems.

Strategic focus Strong emphasis on colorectal disease screening and rapid 5-minute results can be leveraged to form collaborations with primary care networks, gastroenterology groups, and digital health platforms seeking efficient, scalable diagnostic solutions.